Amarantus Bioscience Holdings Inc (AMBS)

[68-Tele]

5 of the 6 patients in the first cohort have been dosed:
"Our collaborator UCSF is working with the NIH to conduct a Phase I clinical trial of a gene therapy for Parkinson’s disease consisting of an AAV2-based vector carrying the GDNF gene we have exclusively licensed, produced in a third party mammalian cell-based manufacturing process. This trial is sponsored and funded by the NIH. The aim of this clinical trial is to introduce the GDNF gene to provide a consistent supply of GDNF to the relevant areas of the brain. In this clinical trial, the NIH is using convection enhanced delivery with the goal of achieving more precisely targeted administration than the methods used in early approaches, which may result in improved efficacy."
I see a high probability of MANF following the same roadmap
as Uni***e